Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01084824 · ClinicalTrials.gov registry record · NA
A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin
A NA study of Verruca Vulgaris, sponsored by North Idaho Dermatology.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01084824: Completed NA study of Verruca Vulgaris, sponsored by North Idaho Dermatology.
NCT01084824 is a NA study of Verruca Vulgaris that has completed, run by North Idaho Dermatology. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01084824, a NA study of Verruca Vulgaris, has completed, sponsored by North Idaho Dermatology.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts, is more effective if it is used alone, or if it is more effective if combined with cantharidin, a topical treatment also commonly used for warts (verruca vulgaris).
Primary Outcome
Percentage of treated warts cleared with treatment, as measured with dermatoscopic examination, after 12 weeks.
Conditions Studied
Interventions
- DRUG Liquid nitrogen and cantharidin
- DRUG Liquid nitrogen and topical placebo
Study Locations (1)
Idaho
- North Idaho Dermatology - Coeur d'Alene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-09 |
| Phase | NA |
What the finished NCT01084824 record still lists
NCT01084824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Verruca Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Liquid nitrogen and cantharidin is the first listed.
NCT01084824 reports a single indexed study location in Idaho.
Frequently Asked Questions
What is clinical trial NCT01084824 about?
NCT01084824 is a clinical study titled "A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin". The purpose of the study was to see if liquid nitrogen, a commonly used treatment for warts, is more effective if it is used alone, or if it is more effective if combined with cantharidin, a topical treatment also commonly used for warts (verruca vulgaris).
What is the current status of trial NCT01084824?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2007-06. Estimated completion is 2008-09.
What conditions does trial NCT01084824 study?
This clinical trial studies the following conditions: Verruca Vulgaris.
What interventions are being tested in trial NCT01084824?
The interventions under investigation include: Liquid nitrogen and cantharidin (DRUG), Liquid nitrogen and topical placebo (DRUG).
Who is sponsoring clinical trial NCT01084824?
This trial is sponsored by North Idaho Dermatology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01084824 being conducted?
This trial has 1 study location across Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Verruca Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01084824's enrollment target sits among peer trials
70 1103rd of 2000 higher than 868 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia